Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
      Antibodies, Anticardiolipin/*metabolism ; Kidney/*drug effects ; Kidney/*physiopathology ; Lupus Coagulation Inhibitor/*metabolism ; Lupus Nephritis/*drug therapy ; Lupus Nephritis/*immunology ; Platelet Aggregation Inhibitors/*pharmacology; Adult ; Antiphospholipid Syndrome/complications ; Cytoprotection/drug effects ; Drug Interactions ; Female ; Glomerular Filtration Rate/drug effects ; Humans ; Immunosuppression Therapy ; Kidney/pathology ; Lupus Nephritis/complications ; Lupus Nephritis/physiopathology ; Male ; Platelet Aggregation Inhibitors/therapeutic use ; Retrospective Studies
    • نبذة مختصرة :
      Objective: We sought to evaluate the effect of antiplatelet therapy in addition to conventional immunosuppressive therapy for lupus nephritis (LN) patients positive for antiphospholipid antibodies (aPL) without definite antiphospholipid syndrome (APS).
      Methods: Patients with biopsy-proven LN class III or IV were retrospectively evaluated. We selected patients positive for anticardiolipin antibody (aCL) or lupus anticoagulant (LA) who did not meet the criteria for a diagnosis of APS. The patients were divided into two subgroups according to whether antiplatelet therapy was received. The cumulative complete renal response (CR) rate, relapse-free rate, and change in estimated glomerular filtration rate (eGFR) over 3 years after induction therapy were calculated.
      Results: We identified 17 patients who received antiplatelet therapy and 21 who did not. Baseline clinicopathological characteristics and immunosuppressive therapy did not show a significant difference between the two groups except for a higher incidence of LN class IV in the treatment group (p = 0.03). There was no difference in cumulative CR rate, relapse-free rate, or eGFR change between these subgroups. However, when data on LA-positive patients were assessed, an improvement in eGFR was found (p = 0.04) in patients receiving antiplatelet treatment.
      Conclusion: Addition of anti-platelet therapy was associated with an improvement of eGFR in LA-positive patients with LN class III or IV.
    • References:
      Rheumatology (Oxford). 2001 Aug;40(8):863-7. (PMID: 11511754)
      Arthritis Rheum. 1997 Sep;40(9):1725. (PMID: 9324032)
      J Rheumatol. 2006 Nov;33(11):2214-21. (PMID: 17014001)
      Rheumatol Int. 2014 Apr;34(4):535-41. (PMID: 24232504)
      Arthritis Rheum. 1996 Mar;39(3):363-9. (PMID: 8607884)
      N Engl J Med. 2011 Dec 1;365(22):2110-21. (PMID: 22129255)
      PLoS One. 2017 Apr 6;12 (4):e0175152. (PMID: 28384208)
      Thromb Haemost. 2001 Aug;86(2):575-83. (PMID: 11522006)
      Autoimmunity. 2004 Jun;37(4):309-12. (PMID: 15518048)
      Arthritis Rheum. 1992 Jun;35(6):630-40. (PMID: 1599520)
      Semin Arthritis Rheum. 2006 Jun;35(6):360-7. (PMID: 16765713)
      Ann Rheum Dis. 2012 Nov;71(11):1771-82. (PMID: 22851469)
      J Am Soc Nephrol. 2002 Jan;13(1):42-52. (PMID: 11752020)
      J Rheumatol. 2000 Mar;27(3):685-91. (PMID: 10743809)
      Immunol Res. 2013 Jul;56(2-3):358-61. (PMID: 23568055)
      J Thromb Haemost. 2004 Oct;2(10):1860-2. (PMID: 15456509)
      J Thromb Haemost. 2006 Feb;4(2):295-306. (PMID: 16420554)
      Lupus. 2014 Oct;23(12):1276-8. (PMID: 25228725)
      Thromb Haemost. 1995 Oct;74(4):1185-90. (PMID: 8560433)
      Arthritis Rheum. 2007 Jul;56(7):2382-91. (PMID: 17599766)
      Thromb Res. 2002 Dec 15;108(5-6):263-71. (PMID: 12676184)
      Kidney Int. 1994 Feb;45(2):544-50. (PMID: 8164443)
      Mod Rheumatol. 2016 Nov;26(6):908-913. (PMID: 27115200)
      Am J Kidney Dis. 2004 Jan;43(1):28-36. (PMID: 14712424)
      J Am Soc Nephrol. 2004 Feb;15(2):241-50. (PMID: 14747370)
      QJM. 1998 Jun;91(6):401-9. (PMID: 9709458)
    • الرقم المعرف:
      0 (Antibodies, Anticardiolipin)
      0 (Lupus Coagulation Inhibitor)
      0 (Platelet Aggregation Inhibitors)
    • الموضوع:
      Date Created: 20180504 Date Completed: 20180801 Latest Revision: 20211204
    • الموضوع:
      20221213
    • الرقم المعرف:
      PMC5933765
    • الرقم المعرف:
      10.1371/journal.pone.0196172
    • الرقم المعرف:
      29723256